Immunotherapy and molecular role of T-cell in PD-1 antibody treated resectable lung cancer patients

In the tumor microenvironment, overexpression of check point molecules, such as program death ligand-1 (PDL1) functions as a protector against the immune surveillance by T-cell through the interaction with program death-1 (PD1) receptor (1). It has been found that PD1 overexpressed on a variety of tumor-killing immune cells, such as monocytes, macrophages, cytotoxic CD8+ T cells, and dendritic cells has an active role in hijacking the antitumor immune response (2).